Intellipharmaceutics International Inc. (IPCI)

[92649]

Doog it will cost a minimum of $20M to $25M just to move along the pipeline in the next two years, which could eat up all the positive cash flows coming in that period. Investors are still concerned with an offering that could be coming especially if Rexista is not tentatively approved. So without new approvals on pipeline drugs or a partnership (s) most investors would consider an investment dead money. Plus all the negatives of current management/ownership concerns.